MIRA Pharmaceuticals announced positive results from a pilot study of SKNY-1, an oral drug candidate for obesity, showing significant reductions in body weight and fat in obese mice without reducing food intake. Unlike semaglutide, SKNY-1 preserved lean mass and showed limited weight regain after treatment stopped, suggesting a unique metabolic mechanism possibly involving energy expenditure. These findings support further development of SKNY-1 as a novel oral obesity treatment with potential advantages for long-term weight management.
MIRA Pharmaceuticals' obesity drug candidate SKNY-1 is highlighted here with Pluang's health sector market context as of Oct 29, 2026 18:11 WIB: out of 150 priced US health stocks, 95 advanced and 47 declined. Leading gainers include Eli Lilly And Co (LLY) at USD 1,341.75 with a 4.11% increase and a typical hold time of 94 days, Amgen, Inc. (AMGN) at USD 468.17 up 3.62%, and Vertex Pharmaceuticals Incorporated (VRTX) at USD 547.98 rising 3.45%. Pluang order activity shows strong buying interest in LLY and AMGN, with 71% and 82% buy orders respectively.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
